Navigation Links
Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Date:3/24/2009

HAYWARD, Calif., March 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data from the first cohort of 30 patients, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol based on favorable interim results.

IMPACTS is a Phase II multi-center clinical trial evaluating the safety and effectiveness of intravenous A-001 (varespladib sodium) in preventing the development of acute chest syndrome in hospitalized sickle cell disease patients. Enrolled patients are at-risk for acute chest syndrome based on the combination of pain (vaso-occlusive crisis)¿ fever¿ and elevated serum level of the enzyme (secretory phospholipase or sPLA2). Acute chest syndrome is a life-threatening complication of sickle cell disease and one of the most common causes of death in this population.

"We look forward to continuing the A-001 trial under our original protocol," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "We believe a drug that is deemed to be safe and able to suppress inflammation by inhibiting sPLA2 provides an opportunity for early intervention for patients where current treatment options are limited."

"Today's announcement marks an exciting milestone for Anthera and more importantly, the sickle cell patient population," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "We are pleased with the continued progress of our varespladib clinical programs for cardiovascular and sickle cell disease where
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
2. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
3. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
4. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
5. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
6. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
7. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
8. New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation
9. Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment
10. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
11. CPR Data Debriefing by Hospital Responders Improves CPR Performance and Increases Initial Survival Rate Following Cardiac Arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PRINCETON, N.J. , Dec. 24, 2014 /PRNewswire/ ... Company), a late-stage biopharmaceutical company developing products that ... inflammation, oncology and biodefense, announced today that on ... registered public offering. The Company raised ... offering and intends to use the net proceeds ...
(Date:12/24/2014)... and LONDON , December 24, 2014 ... are expected to grow at an average rate of ... value and volume. Hip, knee and spine surgeries are ... in emerging economies they have a lower penetration. Increased ... the use of composites. Non-metallic orthopedic devices have gained ...
(Date:12/24/2014)... 2014 LifeScienceIndustryResearch.com adds ... Syringe Industry of 178 pages providing 10 ... library. The 2014 Market Research ... a professional and deep research report on ... the report introduces Disposable Syringe basic information ...
Breaking Medicine Technology:Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 2World Disposable Syringe Market 2014 Report: China and Regional Analysis 3World Disposable Syringe Market 2014 Report: China and Regional Analysis 4World Disposable Syringe Market 2014 Report: China and Regional Analysis 5
... , May 8 Inverness Medical Innovations, Inc. (NYSE: ... take charge of their health at home through the merger of ... the Bank of America Merrill Lynch Health Care Conference being held ... in New York, New York .  Jon Russell, Vice President, ...
... SWANTON, Vt ., May 7 This May, ... in their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness ... at www.allerair.com .  Additionally, their blogs and articles ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... on a "fountain of youth" drug that can delay the ... a new study suggests. Seniors received a significant boost ... a genetic signaling pathway linked to aging and immune function, ... The experimental medication, a version of the drug rapamycin, improved ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 25, 2014 Plugin creators from Pixel ... A fully customizable business presentation tool made specifically for ... ProFire 5k business tool, users can now display their ... of Pixel Film Studios. “ProFire 5k gives users a ... add professionalism to a presentation” , Pixel Film Studios ...
(Date:12/25/2014)... CA (PRWEB) December 25, 2014 Each ... visits and 2 million hospital admissions across the nation ... Prevention ). The CDC’s National Hospital Ambulatory Medical ... through a survey conducted in 2010. They estimated that ... visits that resulted in a primary diagnosis of broken ...
(Date:12/24/2014)... Wi (PRWEB) December 25, 2014 AlignLife ... are unable to afford certain items. During the holiday season, ... "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, owner ... and staff such joy, knowing that we are able to ... present had it not been for the generosity of our ...
Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2
... prescription drugs , THURSDAY, April 8 (HealthDay News) -- Medical ... included -- are poorly informed about herbal medicines and that ... misplaced, according to a new survey. , The survey was ... and Therapeutics Bulletin , which published the results online April ...
... ... Research Behind Their Products , ... Provo, UT (Vocus) April 8, 2010 -- Tahitian Noni International (TNI) now has ... are on the way. TNI has more human clinical studies than any network marketing superfruit ...
... Thomas Mower Sr., Chairman of ... in the growth and success of Sportsmen for Fish and Wildlife (SFW), according to Founder Don ... Salt Lake City (PRWEB) April ... of the Utah Jazz, have been key players in the growth and success of Sportsmen for ...
... ... Medical Design Excellence Awards competition, one of the most prestigious awards in the medical ... ... recognized in the 2010 Medical Design Excellence Awards competition, one of the most prestigious ...
... ... week to discuss how to start your own porn site. , ... (PRWEB) April 8, 2010 -- The Phoenix Forum is Thursday, April 8th ... of Teleteria would love to go over ways to improve your traffic and revenue stream in ...
... ... and positioning of healthcare technology solutions. , ... (PRWEB) April 8, 2010 -- CapSite™ Consulting, ... comparisons of contracts and proposals for Healthcare IT, Imaging Equipment and Medical Device ...
Cached Medicine News:Health News:Insight on Herbals Eludes Doctors, Patients Alike 2Health News:14 Human Clinical Studies Prove the Efficacy of Tahitian Noni Bioactive Beverages 2Health News:Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization 2Health News:Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization 3Health News:Thomas E. Mower And Karl Malone Instrumental To Success Of Sportsmen For Fish And Wildlife Organization 4Health News:ROBRADY Design's Work with Xhale Innovations Inc. Wins 2010 Medical Design Excellence Awards 2Health News:ROBRADY Design's Work with Xhale Innovations Inc. Wins 2010 Medical Design Excellence Awards 3Health News:Jay Servidio President Teleteria Appearances To Discuss The Porn Business This Week 2Health News:CapSite™ Provides Detailed Transparency on Healthcare Technology Purchases 2
... agitators offer a wide range of storage ... drawer storage platform to agitate smoothly, eliminating ... down and squeak. Sturdy, one-piece perforated drawers ... circulation for your platelets., ,i.Series platelet agitators ...
Platelet agitator....
Reciprocating shaker specifically for platelet bags....
I-125 competitive RIA kit for the detection of Progesterone....
Medicine Products: